Trial Profile
A Randomized Open-Label Study of 400 mg Versus 800 mg of Gleevec/Glivec (Imatinib Mesylate) in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms TOPS
- Sponsors Novartis
- 07 Feb 2012 Results published in the Haematologica.
- 02 Feb 2012 Trial acronym (TOPS) identified as reported by ClinicalTrials.gov.
- 02 Feb 2012 Trial acronym (TOPS) identified as reported by ClinicalTrials.gov.